Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-11
2006-07-11
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S512000, C540S513000
Reexamination Certificate
active
07074783
ABSTRACT:
Disclosed are compounds, which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit increased potency and are expected to also exhibit an increased duration of action.
REFERENCES:
patent: 3654275 (1972-04-01), McManus
patent: 43 41 663 (1995-06-01), None
patent: 02/099388 (2002-12-01), None
patent: 03/007958 (2003-01-01), None
patent: 2004/033436 (2003-04-01), None
patent: 03/093245 (2003-11-01), None
Menke, et al., “Expression Cloning of a Human B1Bradykinin Receptor”, J. Biol. Chem., 269(34):21583-21586 (1994).
Hess, et al., “Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor”, Biochem Biophys. Res. Commun., 184:260-268 (1992).
Burch, et al., “Bradykinin Receptor Antagonists”, Med., 30:237-269 (1990).
Ammons, et al., “Effects of Intracardiac Bradykinin on T2-T5Medial Spinothalamic Cells”, The American Physiological Society, 0363-6119, R147-R152 (1985).
Costello, et al., “Suppression of Carageenan-Induced Hyperalgesia, Hyperthermia and Edema by a Bradykinin Antagonist”, European Journal of Pharmacology, 171:259-263 (1989).
Laneuville, et al., “Bradykinin Analogue Blocks Bradykinin-induced Inhibition of a Spinal Nociceptive Reflex in the Rat”, European Journal of Pharmacology, 137:281-285 (1987).
Steranka, et al., “Antinociceptive Effects of Bradykinin Antagonists”, European Journal of Pharmacology, 136:261-262 (1987).
Steranka, et al., “Bradykinin as a Pain Mediator: Receptors are Localized to Sensory Neurons, and Antagonists have Analgesic Actions”, Neurobiology, 85:3245-3249 (1988).
Whalley, et al., “The Effect of Kinin Agonists and Antagonists on the Pain Response of the Human Blister Base”, Naunyn Schmiederberg's Arch. Pharmacol., 336:652-655 (1987).
Back, et al., “Determination of Components of the Kallikrein-Kinin System in the Cerebrospinal Fluid of Patients with Various Diseases”, Res. Clin. Stud. Headaches, 3:219-226 (1972).
Ness, et al., “Visceral Pain: a Review of Experimental Studies”, Pain, 41:167-234 (1990).
Aasen, et al., “Plasma kallikrein Activity and Prekallikrein Levels during Endotoxin Shock in Dogs”, Eur. Surg. Res., 10:50-62(1978).
Aasen, et al., “Plasma Kallikrein-Kinin System in Septicemia”, Arch. Surg., 118:343-346 (1983).
Katori, et al., “Evidence for the Involvement of a Plasma Kallikrein-Kinin System in the Immediate Hypotension Produced by Endotoxin in Anaesthetized Rats”, Br. J. Pharmacol., 98:1383-1391 (1989).
Marceau, et al., “Pharmacology of Kinins: Their Relevance to Tissue Injury and Inflammation”, Gen. Pharmacol., 14:209-229 (1983).
Weipert, et al., “Attenuation of arterial blood pressure fall endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp2, Thi5,8, DPhe7]-BK (B4148)”, Brit J. Pharm., 94:282-284 (1988).
Haberland, “The Role of Kininogenases, Kinin Formation and Kininogenase Inhibition in Post Traumatic Shock and Related Conditions”, Klinische Woochen-Schrift, 56:325-331 (1978).
Ellis, et al., “Inhibition of Bradykinin-and Kallikrein-Induced Cerebral Arteriolar Dilation by Specific Bradykinin Antagonist”, Stroke, 18:792-795 (1987).
Kamitani, et al., “Evidence for a Possible Role of the Brain Kallikrein-Kinin System in the Modulation of the Cerebral Circulation”, Circ. Res., 57:545-552 (1985).
Barnes, “Inflammatory Mediator Receptors and Asthma”, Am. Rev. Respir. Dis., 135:S26-S31 (1987).
Burch, et al., “Bradykinin Receptor Antagonists”, Med Res. Reviews., 10::237-269 (1990).
Fuller, et al., “Bradykinin-induced Bronchoconstriction in Humans”, Am. Rev. Respir. Dis., 135:176-180 (1987).
Jin, et al., “Inhibition of Bradykinin-Induced Bronchoconstriction in the Guinea-Pig by a Synthetic B2Receptor Antagonist”, Br. J. Pharmacol., 97:598-602 (1989).
Polosa, et al., “Contribution of Histamine and Prostanoids to Bronchoconstriction Provoked by Inhaled Bradykinin in Atopic Asthma”, Allergy, 45:174-182 (1990).
Baumgarten, et al., “Concentrations of Glandular Kallikrein in Human Nasal Secretions Increase During Experimentally Induced Allergic Rhinitis”, J. Immunology, 137:1323-1328 (1986).
Proud, et al., “Nasal Provocation with Bradykinin Induces Symptoms of Rhinitis and a Sore Throat”, Am. Rev. Respir Dis., 137:613-616 (1988).
Seabrook, et al., “Expression of B1and B2Bradykinin Receptor mRNA and Their Functional Roles in Sympathetic Ganglia and Sensory Dorsal Root Ganglia Neurons from Wild-type and B2Receptor Knockout Mice”, Neuropharmacology, 36(7):1009-17 (1997).
Elguero, et al., Nonconventional Analgesics: Bradykinin Antagonists, An. Real. Acad. Farm., 63:173-190 (1997).
Artis, et al., “Structured-based design of Six novel classes of nonpeptide antagonists of the bradykinin B2receptor”, Bioganic & Med. Chem. Letters, 10:2421-2425, (2000).
Dziadulewicz, et al., “The design of non-peptide human bradykinin B2receptor antagonists employing the benzodiazepine peptidomimetic scaffold”, Bioganic & Med. Chem. Letters, 9:463-468, (1999).
Grant Francine S.
Holcomb Ryan C.
Pleiss Michael A.
Thorsett Eugene D.
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
Kifle Bruck
LandOfFree
Sulfonylbenzodiazepinone acetamides as bradykinin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonylbenzodiazepinone acetamides as bradykinin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylbenzodiazepinone acetamides as bradykinin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3573944